Which has better valuation & earnings, GDR or GENI?

GENinCode has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio genedrive £929K 16.07 -£21.22M -£0.79 N/A GENinCode £2.60M 1.69 -£6.10M -£1.27 N/A

Is GDR or GENI more profitable?

GENinCode has a net margin of -202.42% compared to genedrive's net margin of -500.75%. GENinCode's return on equity of -481.34% beat genedrive's return on equity. Company Net Margins Return on Equity Return on Assets genedrive -500.75% -1,044.57% -74.09% GENinCode -202.42% -481.34% -63.99%

Is AGL or GENI more profitable?

GENinCode has a net margin of -202.42% compared to ANGLE's net margin of -1,560.86%. ANGLE's return on equity of -157.49% beat GENinCode's return on equity. Company Net Margins Return on Equity Return on Assets ANGLE -1,560.86% -157.49% -29.89% GENinCode -202.42% -481.34% -63.99%

Is GENI or VRCI more profitable?

GENinCode has a net margin of -202.42% compared to Verici Dx's net margin of -223.60%. Verici Dx's return on equity of -127.57% beat GENinCode's return on equity. Company Net Margins Return on Equity Return on Assets GENinCode -202.42% -481.34% -63.99% Verici Dx -223.60% -127.57% -26.14%

GENinCode (GENI) Competitors

GBX 0.59 -0.01 (-1.33%)

As of 06:43 AM Eastern

Compare

GENI vs. YGEN, GDR, AGL, PRM, and VRCI

Should you buy GENinCode stock or one of its competitors? GENinCode's main competitors and comparable companies include Yourgene Health (YGEN), genedrive (GDR), ANGLE (AGL), Proteome Sciences (PRM), and Verici Dx (VRCI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does GENinCode compare to Yourgene Health?

GENinCode (LON:GENI) and Yourgene Health (LON:YGEN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

GENinCode has higher earnings, but lower revenue than Yourgene Health. GENinCode is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GENinCode	£2.60M	1.69	-£6.10M	-£1.27	N/A
Yourgene Health	£29.67M	0.00	-£8.17M	-£0.01	N/A

2.8% of GENinCode shares are owned by institutional investors. Comparatively, 23.3% of Yourgene Health shares are owned by institutional investors. 8.4% of GENinCode shares are owned by company insiders. Comparatively, 64.4% of Yourgene Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, GENinCode's average media sentiment score of 0.00 equaled Yourgene Health'saverage media sentiment score.

Company	Overall Sentiment
GENinCode	Neutral
Yourgene Health	Neutral

Yourgene Health has a net margin of -27.55% compared to GENinCode's net margin of -202.42%. Yourgene Health's return on equity of -27.06% beat GENinCode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GENinCode	-202.42%	-481.34%	-63.99%
Yourgene Health	-27.55%	-27.06%	-6.71%

GENinCode has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Yourgene Health has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Summary

Yourgene Health beats GENinCode on 8 of the 10 factors compared between the two stocks.

How does GENinCode compare to genedrive?

genedrive (LON:GDR) and GENinCode (LON:GENI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

0.1% of genedrive shares are owned by institutional investors. Comparatively, 2.8% of GENinCode shares are owned by institutional investors. 28.1% of genedrive shares are owned by company insiders. Comparatively, 8.4% of GENinCode shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, genedrive's average media sentiment score of 0.00 equaled GENinCode'saverage media sentiment score.

Company	Overall Sentiment
genedrive	Neutral
GENinCode	Neutral

GENinCode has a net margin of -202.42% compared to genedrive's net margin of -500.75%. GENinCode's return on equity of -481.34% beat genedrive's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
genedrive	-500.75%	-1,044.57%	-74.09%
GENinCode	-202.42%	-481.34%	-63.99%

genedrive has a beta of 1.004, suggesting that its share price is 0% more volatile than the broader market. Comparatively, GENinCode has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

GENinCode has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
genedrive	£929K	16.07	-£21.22M	-£0.79	N/A
GENinCode	£2.60M	1.69	-£6.10M	-£1.27	N/A

Summary

GENinCode beats genedrive on 7 of the 11 factors compared between the two stocks.

How does GENinCode compare to ANGLE?

ANGLE (LON:AGL) and GENinCode (LON:GENI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

GENinCode has lower revenue, but higher earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANGLE	£2.62M	2.89	-£21.76M	-£4.80	N/A
GENinCode	£2.60M	1.69	-£6.10M	-£1.27	N/A

In the previous week, ANGLE's average media sentiment score of 0.00 equaled GENinCode'saverage media sentiment score.

Company	Overall Sentiment
ANGLE	Neutral
GENinCode	Neutral

17.5% of ANGLE shares are held by institutional investors. Comparatively, 2.8% of GENinCode shares are held by institutional investors. 2.7% of ANGLE shares are held by company insiders. Comparatively, 8.4% of GENinCode shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

GENinCode has a net margin of -202.42% compared to ANGLE's net margin of -1,560.86%. ANGLE's return on equity of -157.49% beat GENinCode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANGLE	-1,560.86%	-157.49%	-29.89%
GENinCode	-202.42%	-481.34%	-63.99%

ANGLE has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, GENinCode has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

Summary

GENinCode beats ANGLE on 6 of the 11 factors compared between the two stocks.

How does GENinCode compare to Proteome Sciences?

Proteome Sciences (LON:PRM) and GENinCode (LON:GENI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Proteome Sciences has higher revenue and earnings than GENinCode. Proteome Sciences is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Proteome Sciences	£3.77M	1.14	-£4.08M	-£0.72	N/A
GENinCode	£2.60M	1.69	-£6.10M	-£1.27	N/A

Proteome Sciences has a beta of 0.157, meaning that its stock price is 84% less volatile than the broader market. Comparatively, GENinCode has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

0.0% of Proteome Sciences shares are held by institutional investors. Comparatively, 2.8% of GENinCode shares are held by institutional investors. 36.7% of Proteome Sciences shares are held by company insiders. Comparatively, 8.4% of GENinCode shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Proteome Sciences' average media sentiment score of 0.00 equaled GENinCode'saverage media sentiment score.

Company	Overall Sentiment
Proteome Sciences	Neutral
GENinCode	Neutral

Proteome Sciences has a net margin of -61.46% compared to GENinCode's net margin of -202.42%. Proteome Sciences' return on equity of 23.85% beat GENinCode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Proteome Sciences	-61.46%	23.85%	-19.25%
GENinCode	-202.42%	-481.34%	-63.99%

Summary

Proteome Sciences beats GENinCode on 7 of the 11 factors compared between the two stocks.

How does GENinCode compare to Verici Dx?

GENinCode (LON:GENI) and Verici Dx (LON:VRCI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

2.8% of GENinCode shares are owned by institutional investors. Comparatively, 9.9% of Verici Dx shares are owned by institutional investors. 8.4% of GENinCode shares are owned by company insiders. Comparatively, 1.1% of Verici Dx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

GENinCode has a net margin of -202.42% compared to Verici Dx's net margin of -223.60%. Verici Dx's return on equity of -127.57% beat GENinCode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GENinCode	-202.42%	-481.34%	-63.99%
Verici Dx	-223.60%	-127.57%	-26.14%

GENinCode has higher earnings, but lower revenue than Verici Dx. GENinCode is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GENinCode	£2.60M	1.69	-£6.10M	-£1.27	N/A
Verici Dx	£3.52M	3.97	-£6.56M	£0.10	2.10

GENinCode has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Verici Dx has a beta of 1.222, indicating that its share price is 22% more volatile than the broader market.

In the previous week, GENinCode's average media sentiment score of 0.00 equaled Verici Dx'saverage media sentiment score.

Company	Overall Sentiment
GENinCode	Neutral
Verici Dx	Neutral

Summary

Verici Dx beats GENinCode on 8 of the 11 factors compared between the two stocks.

Get GENinCode News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GENI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GENI vs. The Competition

Export

Metric	GENinCode	Life Sciences Tools & Services Industry	Healthcare Sector	LON Exchange
Market Cap	£4.46M	£11.14B	£7.87B	£2.81B
Dividend Yield	N/A	1.46%	2.47%	5.09%
P/E Ratio	-0.47	54.63	33.78	23.20
Price / Sales	1.72	7.62	8.96	5.06
Price / Cash	0.83	27.21	21.62	20.23
Price / Book	0.36	4.74	4.93	2.44
Net Income	-£6.10M	£57.48B	£3.51B	£5.88B
7 Day Performance	-1.66%	2.91%	1.58%	-0.76%
1 Month Performance	-7.93%	-0.36%	-3.74%	-1.49%
1 Year Performance	-76.55%	27.75%	3.31%	7.32%

GENinCode Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GENI GENinCode	N/A	GBX 0.59 -1.3%	N/A	-76.2%	£4.46M	£2.60M	N/A	2,300	High Trading Volume
YGEN Yourgene Health	N/A	N/A	N/A	N/A	£16.43M	£29.67M	N/A	253
GDR genedrive	N/A	GBX 1 +2.6%	N/A	+1.6%	£16.06M	£929K	N/A	43
AGL ANGLE	N/A	GBX 2.35 -11.3%	N/A	+0.0%	£7.58M	£2.62M	N/A	650	Gap Up
PRM Proteome Sciences	N/A	GBX 1.58 +8.7%	N/A	-12.0%	£5.53M	£3.77M	N/A	240	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:GENI) was last updated on 11/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GENinCode (GENI) Competitors

GENI vs. YGEN, GDR, AGL, PRM, and VRCI

How does GENinCode compare to Yourgene Health?

Summary

How does GENinCode compare to genedrive?

Summary

How does GENinCode compare to ANGLE?

Summary

How does GENinCode compare to Proteome Sciences?

Summary

How does GENinCode compare to Verici Dx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENI vs. The Competition

GENinCode Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GENinCode (GENI) Competitors

GENI vs. YGEN, GDR, AGL, PRM, and VRCI

How does GENinCode compare to Yourgene Health?

Which has higher earnings and valuation, GENI or YGEN?

Do insiders & institutionals have more ownership in GENI or YGEN?

Does the media refer more to GENI or YGEN?

Is GENI or YGEN more profitable?

Which has more risk & volatility, GENI or YGEN?

Summary

How does GENinCode compare to genedrive?

Do insiders and institutionals believe in GDR or GENI?

Does the media prefer GDR or GENI?

Is GDR or GENI more profitable?

Which has more volatility & risk, GDR or GENI?

Which has better valuation & earnings, GDR or GENI?

Summary

How does GENinCode compare to ANGLE?

Which has better earnings & valuation, AGL or GENI?

Does the media prefer AGL or GENI?

Do institutionals & insiders have more ownership in AGL or GENI?

Is AGL or GENI more profitable?

Which has more volatility and risk, AGL or GENI?

Summary

How does GENinCode compare to Proteome Sciences?

Which has stronger earnings and valuation, PRM or GENI?

Which has more risk and volatility, PRM or GENI?

Do institutionals & insiders hold more shares of PRM or GENI?

Does the media favor PRM or GENI?

Is PRM or GENI more profitable?

Summary

How does GENinCode compare to Verici Dx?

Do insiders and institutionals believe in GENI or VRCI?

Is GENI or VRCI more profitable?

Which has better valuation and earnings, GENI or VRCI?

Which has more risk and volatility, GENI or VRCI?

Does the media favor GENI or VRCI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENI vs. The Competition

GENinCode Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools